Drugmakers Turn to Gyms and Metros to Drive China Weight-Loss Sales
In this article (7)
Global and local drugmakers are plastering Chinese metro stations, gyms, and sports stadiums with obesity campaigns to capture a 30 billion yuan weight-loss market. China bans direct-to-consumer advertising for prescription medicines, forcing pharmaceutical companies to sell lifestyle interventions rather than brand names to a population where overweight rates could top 65 per cent by 2030.
Eli Lilly, Novo Nordisk, Pfizer, and domestic group Innovent Biologics are vying for early dominance in once-weekly GLP-1 injections. In the second quarter, Lilly took the top spot in sales on Alibaba’s Tmall and JD.com, according to Jefferies data. To sustain demand, companies place unbranded warnings about sleep apnoea and fatty liver disease in high-traffic public transit hubs and fitness chains.
Sidestepping the Ban on Drug Ads
Regulations permit pharmaceutical brands to discuss disease symptoms publicly, provided they omit specific prescription product names. Lilly ran subway displays in Shanghai’s Jing’an district alerting commuters to the links between snoring and excess weight, while Innovent partnered with delivery giant Meituan on transit billboards highlighting fatty liver reversal. Innovent also promoted weight management messages during football matches in Suzhou and featured a mascot named Madudu, echoing the generic name of its mazdutide injection.
“JP Morgan projects that total will hit 30 billion yuan, or roughly $4 billion, within five to seven years.”
Pfizer collaborated with gym chain Supermonkey on public workout events in Shanghai. State broadcaster CCTV worked with Novo Nordisk on a public health exhibit in Beijing featuring group dancing. These street campaigns drive consumers directly to hospital consultation rooms. Doctors at clinics in Shanghai and Guangzhou report that patients increasingly ask for specific treatments by name, shifting from Novo’s semaglutide to Lilly’s tirzepatide and Innovent’s mazdutide.
The Race for a Four Billion Dollar Market
China’s prescription weight-loss segment generates between 3 billion and 4 billion yuan today. JP Morgan projects that total will hit 30 billion yuan, or roughly $4 billion, within five to seven years. Novo Nordisk started the race with a late 2024 rollout, Lilly entered in January 2025, Pfizer issued its first prescriptions in April, and Innovent rolled out its drug in July 2025.
RetailNews Asia notes that healthcare brands across East Asia have long used subtle educational pushes to bypass medical marketing restrictions, but the intensity in China now mirrors consumer FMCG marketing more than traditional clinical outreach. Competitors are actively adjusting their public phrasing to match consumer vocabulary, moving budget away from purely hospital-focused sales representatives.
Regulators in the region are watching the grey area closely. Lilly paused an obesity awareness campaign in India earlier this year after local authorities raised concerns that public outreach coincided directly with the market launch of Mounjaro. In China, market regulators will determine whether mascot branding and metro displays cross into unlawful prescription drug promotion as rollout volumes climb through the end of 2026.
Questions & Answers
Q.Why are drugmakers focusing on lifestyle interventions rather than specific brand names in their Chinese campaigns?
Why are drugmakers focusing on lifestyle interventions rather than specific brand names in their Chinese campaigns?
China prohibits direct-to-consumer advertising for prescription medicines. This forces pharmaceutical companies to promote general lifestyle changes instead of particular drug brands to the population.
Q.What examples show how drugmakers are advertising without naming specific prescription products?
What examples show how drugmakers are advertising without naming specific prescription products?
Lilly used subway displays highlighting links between snoring and weight, while Innovent partnered with Meituan on billboards about fatty liver reversal. Pfizer also held public workout events with Supermonkey.
Q.How much is the current prescription weight-loss market in China worth, and what is its projected growth?
How much is the current prescription weight-loss market in China worth, and what is its projected growth?
The current market generates between 3 billion and 4 billion yuan. JP Morgan projects this total will reach 30 billion yuan, or roughly $4 billion, within five to seven years.
Q.Which drugmakers are currently leading in the race for dominance in the Chinese weight-loss market?
Which drugmakers are currently leading in the race for dominance in the Chinese weight-loss market?
Eli Lilly, Novo Nordisk, Pfizer, and Innovent Biologics are all competing for market share. Lilly took the top spot in sales on Tmall and JD.com in the second quarter.
Reader pulse
Is this marketing strategy sustainable?
21,219 votes so far